<DOC>
	<DOCNO>NCT01270295</DOCNO>
	<brief_summary>RAGE , receptor advance glycation end product , novel marker alveolar epithelial type I cell injury . Soluble RAGE ( sRAGE ) elevate plasma pulmonary edema fluid patient ALI/ARDS , one acknowledge RAGE/NF-B axis also involved pathophysiology various condition . Few data available level soluble form ligands RAGE setting ALI/ARDS . The purpose observational prospective study describe soluble form ( sRAGE , esRAGE ) ligands RAGE ( HMGB-1 , S100A12 , AGEs ) level ICU patient ALI/ARDS .</brief_summary>
	<brief_title>Soluble Forms Ligands RAGE ALI/ARDS ( SoLiRAGE ) .</brief_title>
	<detailed_description>BACKGROUND : The receptor advance glycation end product ( RAGE ) identify marker alveolar type I cell injury . RAGE member immunoglobulin superfamily act multiligand receptor involve propagate inflammatory response . While precise function RAGE remain unclear , elevated level RAGE , soluble isoform sRAGE , correlate severity ALI/ARDS human animal study , RAGE level could reflect impaired alveolar fluid clearance . Frequently , biology RAGE coincide setting ligand receptor accumulate , especially proinflammatory environment . More work need u understand mechanisms RAGE regulate ALI/ARDS , especially regard expression soluble form involvement potential ligand . DESIGN NARRATIVE : This observational prospective clinical study describe compare soluble form ( sRAGE , esRAGE ) ligands RAGE ( HMGB-1 , S100A12 , AGEs ) level alveolar edema fluid plasma ICU patient enrol within first 24 hour onset ALI/ARDS , patient mechanical ventilation ( control group ) . Edema fluid plasma sample collect simultaneously day 1 , day 3 day 6 , order describe kinetics evolution soluble form ligands RAGE level . Undiluted pulmonary edema fluid sample collect intubated patient , blood sample simultaneously gather indwell arterial central venous catheter . The concentration soluble form ( sRAGE , esRAGE ) ligands RAGE ( HMGB-1 , S100A12 , AGEs ) measure duplicate ELISA .</detailed_description>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<criteria>ICU patient mechanical ventilation Patients within first 24 hour onset ALI/ARDS accord 1994 AmericanEuropean Consensus Conference ( AECC ) Pregnancy Acute exacerbation diabetes Dialysis endstage kidney disease Alzheimer 's disease Amyloidosis Evolutive neoplastic lesion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Receptor advance glycation end product ( RAGE )</keyword>
	<keyword>Soluble RAGE ( sRAGE )</keyword>
	<keyword>Endogenous secretory RAGE ( esRAGE )</keyword>
	<keyword>High-mobility group box-1 protein ( HMGB-1 )</keyword>
	<keyword>Extracellular newly-identified RAGE-binding protein ( EN-RAGE S100A12 )</keyword>
	<keyword>Advanced glycation endproducts ( AGEs )</keyword>
	<keyword>Pentosidine</keyword>
	<keyword>N -- carboxymethyllysine</keyword>
	<keyword>Acute lung injury ( ALI )</keyword>
	<keyword>Acute respiratory distress syndrome ( ARDS )</keyword>
	<keyword>Alveolar epithelium</keyword>
	<keyword>Mechanical ventilation</keyword>
	<keyword>Intensive Care Unit ( ICU )</keyword>
</DOC>